MedTrace Logo

Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma

NCT02585479 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2019-06-04

No results posted yet for this study

Summary

The purpose of this study is to determine that systemic chemotherapy is superior to transcatheter arterial chemoembolization in prolonging progression-free survival（PFS） in patients with Advanced Hepatocellular Carcinoma.

Conditions

Interventions

DRUG

Pirarubicin

1. Pirarubicin 30mg/m2 intravenously 2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries

DRUG

Oxaliplatin

1. Oxaliplatin 100 mg/m2 intravenously 2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries

DRUG

Lipiodol

Lipiodol 5-10ml infused through the right and left hepatic arteries

DEVICE

Gelfoam

Hepatic artery embolization with Gelfoam.

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Lequn Li, PhD · Affiliated Tumor Hospital, Guangxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-10-31
Completion
2017-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585479 on ClinicalTrials.gov